Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-03-13
2007-03-13
Brumback, Brenda (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C530S350000
Reexamination Certificate
active
10321962
ABSTRACT:
The present invention is based upon methods of treating inflammatory conditions in the intestinal tract of mammals using growth factor related polypeptides. The invention includes methods of reducing the mortality rate or delaying mortality in a subject suffering from an inflammatory pathology. Methods of using fibroblast growth factor-CX (FGF-CX) polynucleotides sequences and the FGF-CX polypeptides encoded by such nucleic acid sequence, or variants, fragments and homologs thereof, are claimed in the invention. Similarly, methods of using FCTRX polynucleotide sequences and the FCTRX polypeptides encoded by such nucleic acid sequences, or variants, fragments and homologs thereof, alone or in combination, are also claimed in the invention. FCTRX collectively refers to any of six variant FCTRX sequences, variously designated FCTR1, FCTR2, FCTR3, FCTR4, FCTR5 and FCTR6.
REFERENCES:
patent: 6797695 (2004-09-01), Itoh et al.
patent: 6982250 (2006-01-01), Lichenstein et al.
patent: 2002/0001825 (2002-01-01), Itoh
patent: 2 365 869 (2002-02-01), None
patent: WO 00/54813 (2000-09-01), None
patent: WO 01/07595 (2001-02-01), None
patent: WO 01/31008 (2001-05-01), None
patent: WO 01/68854 (2001-09-01), None
patent: WO 01/72957 (2001-10-01), None
patent: WO 01/92522 (2001-12-01), None
patent: WO 02/02625 (2002-01-01), None
patent: WO 02/24234 (2002-03-01), None
patent: WO 02/36732 (2002-05-01), None
patent: WO 02/46424 (2002-06-01), None
Jeffers et al. A Novel Human Fibroblast Growth Factor Treats Experimental Intestinal Inflammation. 2002, Gastroenterology, vol. 123, pp. 1151-1162.
Ornitz et al. Fibroblast growth factor. 2001, Genome Biology, 2(3), pp. 3005.1-3005.12.
Bikfalvi, et al. (1997). Endocrine Reviews 18: 26-45.
Invitation to Pay Additional Fees for PCT/US 02/19400, mailed Apr. 18, 2003.
Kirikoshi,.et al. (2000). Biochem and Biophys Res Comm 274: 337-343.
International Search Report for PCT/US 01/43846, mailed May 9, 2003.
Bange et al. (2002).Cancer Res62: 840-847.
Ohmachi et al. (2000).Biochem and Biophysical Res Comm277: 355-360.
Wong et al. (2001).Am J of Medical Genetics102: 282-285.
International Search Report for PCT/US02/19400 mailed Jun. 4, 2003.
Jeffers Michael E.
LaRochelle William J.
Lichenstein Henri S.
Biswas Naomi
Brumback Brenda
CuraGen Corporation
Elrifi Ivor R.
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
LandOfFree
Treatment of inflammatory bowel disease using fibroblast... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of inflammatory bowel disease using fibroblast..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of inflammatory bowel disease using fibroblast... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3788125